Utility of iRECIST for evaluating treatment efficacy in patients receiving immune checkpoint inhibitors
Although PP incidence remains low, these findings suggest that continuing treatment beyond initial progression may be beneficial in select cases. However, since this study is retrospective, further validation is necessary.
Authors
- Yuri Tenjimbayashi
- Masafumi Yoshino (ORCID: https://orcid.org/0000-0002-2943-6196)
- Azusa Akiyama
- Yusuke Kobayashi (ORCID: https://orcid.org/0000-0002-4503-2845)
- Asami Suto
- Kaori Ono (ORCID: https://orcid.org/0000-0002-7872-0839)
- Kaoru Fujieda (ORCID: https://orcid.org/0000-0002-5064-8046)
- Takuya Kuboya
- Toyomi Satoh (ORCID: https://orcid.org/0000-0002-6929-5463)
- Takeo Minaguchi (ORCID: https://orcid.org/0000-0003-3577-5124)
- Mizuki ISAYAMA
- Sari Nakao
- Genta Irie
- Ayaka Tsuihiji
- Ayumi Shikama
- Kaori Takeuchi
Institutions
- University of Tsukuba (JP)
Publication Details
- Journal
- Journal of Gynecologic Oncology
- Published
- 2026-01-01
- DOI
- https://doi.org/10.3802/jgo.2026.37.e47
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00